340B Compliance: The Medicaid Exclusion File and Prevention of Duplicate Discounts
July 15th 2018Health care providers participating in the 340B program are prohibited from contributing to duplicate discounts, or the scenario that exists when a manufacturer provides a discounted 340B price and a rebate to Medicaid for the same drug.
Risks, Diagnosis, and Treatment of Non-Hodgkin Lymphoma
Non-Hodgkin’s lymphoma (NHL) was the seventh most prevalent form of cancer in the United States in 2017, according to the National Cancer Institute.
Precision Pharmacotherapy: Ready for Prime Time?
July 11th 2018In general, there is a lack of adequate evidence from well-designed, controlled clinical trials demonstrating that the use of pharmacogenomic data to individualize drug therapy is directly related to improvements in clinical outcome in nononcology therapeutic areas.